European Regulatory Affairs Limited Shortlisted for the Waterford Business Awards 2026

Recognizing our commitment to pharmaceutical regulatory excellence, client partnerships and delivering practical solutions for the pharmaceutical industry. We are delighted to announce that ERA has been shortlisted for the Waterford Business Awards 2026 – a significant milestone for our team and a proud moment for our business. The shortlist recognizes the hard work, dedication and […]

Regulatory Guidance updates in August 2026

  Title:  Regulatory Guidance updates in August 2026. Body text: Regulatory Guidance updates in August 2026 – ERA have tracked them for you! HPRA (IE):  Updated HPRA Guide to the Clinical Trials Regulation to reflect the full implementation of the Clinical Trials Regulation (CTR) to align with current European and national guidance and best practices […]

Regulatory Guidance updates in July 2026

Regulatory Guidance updates in July 2026 – ERA have tracked them for you! HPRA (IE):  The SoHO Regulation: all you need to know to get started guideline was published by the HPRA Are you involved in activities concerning Substances of Human Origin (SoHO) intended for human applications? Are you a facility where SoHO are applied […]

Regulatory Guidance updates in June 2026

Regulatory Guidance updates in June 2026 – ERA have tracked them for you! HPRA (IE):  HPRA webinar – There was a webinar held on the 19th June 2026 on recent updates and developments in the veterinary medicine regulation A recording should be made available in due course Guidance on “Submitting a Request for a New […]

ICH M4Q(R2): The Exciting Evolution of eCTD Modules 2.3 and 3.2

ICH M4Q(R2), “The Common Technical Document for the Registration of Pharmaceuticals for Human Use” is a revised draft version of the guidance that outlines how the quality sections of your medicinal product dossier are presented. ICH M4Q(R2) was signed off as a Step 2 document in May 2025. Public consultation closed in October 2025. In […]

Regulatory Guidance Updates in May 2026

Did you know that the following Regulatory Guidance was updated in May 2026? HPRA (IE):  Promoting medicines to the public on social media – the HPRA has launched a new webpage, setting out clear information on the laws that apply to advertising human medicines for the public HPRA webinar – There will be a webinar […]

Regulatory Guidance updates in March and April 2026

Did you know that the following Regulatory Guidance was updated in March and April 2026? HPRA (IE):  HPRA guidance issued in relation to EMA list of ingredients restricted or prohibited for use in cosmetics from 1st May 2026 CTCG Guidance and Webinar: New Article 11 Workaround for Clinical Trials: The Clinical Trials Coordination Group (CTCG) […]

Post Approval Change Management Protocols (PACMP)

So what is a Post Approval Change Management Protocol (PACMP) The post approval change management protocol (PACMP) was introduced in the EU through the European Commission Guidelines on variation categories. It is a regulatory tool which allows the management of specific quality change(s) in a more predictable and efficient manner, during the lifecycle of a […]

Back to Basics – Biological Medicines

Let’s get Back to Basics – Biological Medicines According to Part I of Annex I of Directive 2001/83/EC, a biological medicinal product is a product that contains a biological substance. A biological substance is a substance that is produced by or extracted from a biological source and that needs for its characterisation and the determination […]

Regulatory Guidance updates in February 2026

Here are the main highlights of Regulatory Guidance updated in February 2026 HPRA (IE):  The HPRA promoted the Facilitating and Accelerating Strategic Clinical Trials (FAST-EU).  FAST-EU is a pilot initiative aiming to accelerate the assessment and authorisation of clinical trials running in multiple EU/EEA countries. The pilot is currently open for submissions and is expected […]

Regulatory Guidance updates in January 2026

Were you aware that the following Regulatory Guidance was updated in January 2026?   HPRA (IE):  Updated fee guidance document for Human medicinal products MHRA (UK):  The MHRA have been very busy updating their website in January – here are some of the highlights Medicines: International Recognition Procedure Updated dates indicating the submission deadlines for […]

Implementation of the revised variations categories – EU and UK

Are you ready to implement the revised variations categories guidance? As of today (15th January 2026) they are to be used for any variation procedure submitted in the EU and UK : EU – New Variations Guidelines in the EC’s Official Journal Regulation (EU) 2024/1701 of 11 March 2024, amending Regulation (EC) No 1234/2008 was […]

Request a Quote